BRAF and Miyoshi myopathy: The goal of this study was to retrospectively assess DDIs to define the risk of drug interactions in clinical practice and their impact on the outcomes of patients with BRAFv600 mutant MM treated with BRAF‐i/MEK‐i inhibitors.